Eli Lilly's weight loss pill shows promising results

Eli Lilly is making progress on a new weight loss pill that uses the same GLP-1 technology as its popular injections. While the pill version doesn’t work as well for weight loss as the shots, it could still be a game-changer for patients who prefer oral medication. The company plans to seek FDA approval by year-end, with hopes of hitting the market by 2026.

Editor’s Note: Weight loss drugs like Ozempic and Mounjaro have been huge, but they require injections—which isn’t ideal for everyone. A pill version could make these treatments more accessible and convenient, even if the results aren’t quite as dramatic. This could open up options for millions of people struggling with obesity, making it a big deal in the healthcare world.

A new study shows that Eli Lilly's experimental weight-loss pill helped participants lose up to 12% of their body weight, potentially paving the way for its market release next year. This pill could offer an alternative to weight-loss injections, though the company's stock dropped by over 10% despite the promising results.

A new daily weight loss pill has shown promising results in trials, with participants losing an average of 12% of their body weight over 72 weeks. This could be a game-changer for people struggling with obesity.

A new pill developed by Eli Lilly has shown significant weight loss results in clinical trials, marking a potential breakthrough in obesity treatment. The drug's success could offer a simpler alternative to existing weight-loss medications, which often require injections.